TXMD on Nasdaq

TherapeuticsMD, Inc.

American pharmaceutical preparations company based in Boca Raton. Summary from the record

Price unavailable

Last updated Oct 19, 2026.

Overview

Compare with Xenetic Biosciences (United States), Aptevo Therapeutics Inc. or Upstream Bio, Inc., or pick any stock.

  • TickerTXMD on Nasdaq2
  • IndustryPharmaceutical Preparations2
  • HeadquartersBoca Raton, United States2
  • Incorporated inNV3
  • Business address951 Yamato Road, Suite 220, Boca Raton, Fl 334313
  • Filer categoryNon-accelerated filer, Smaller reporting company3
  • Legal formCorporation2
  • LEI5299004JS7RE49QHRW302
  • StatusActive2
  • LEI statusLapsed (not renewed)2
  • Registered addressc/o Paracorp Incorporated, 318 N Carson St #208, 89701 Carson City, United States2
  • Registered withBusiness Center (Secretary of State), NV201015484002

See how the biggest companies compare on our leaderboards

2025 10-K Report, this information could prove to be inaccurate as a result of a variety of matters.4 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2025

-145.3%Operating margin5
-18.8%Net margin5
71.6%Revenue growth, 20255
-2.1%Return on equity5

What sells

Revenue by product, business segment and region, as the company reports it to the SEC.

Regions

United States brought in 59% of the revenue TherapeuticsMD, Inc. broke down this way in fiscal 2025.

  1. United States$1.8M559%up 60% from 2024
  2. Outside the United States$1.2M541%up 93% from 2024
Regions by year
Regions20242025
United States$1.1M$1.8M
Outside the United States$638.0K$1.2M

Where the money goes

Where each dollar of revenue went, fiscal 2025

  • Other costs100¢$3.0M

Out of $3.0M in revenue.5 The company lost money this year.

Financial statements

Revenue6785$3.0M in 2025−94% since 2019
0$20.0M$40.0M$60.0M$80.0M2019: $49.6M$49.6M20192020: $64.9M$64.9M2020+31%2021: $2.6M$2.6M2021−96%2022: $70.0M$70.0M2022+2619%2023: $1.3M$1.3M2023−98%2024: $1.8M$1.8M2024+35%2025: $3.0M$3.0M2025+72%
Gross profit679$1.3M in 2023−97% since 2019
0$20.0M$40.0M$60.0M$80.0M2019: $43.3M$43.3M20192020: $48.9M$48.9M2020+13%2021: $1.2M$1.2M2021−98%2022: $68.6M$68.6M2022+5755%2023: $1.3M$1.3M2023−98%
Operating income67985-$4.4M in 2025−97% since 2019
-$200.0M-$150.0M-$100.0M-$50.0M0$50.0M2019: -$151.2M-$151.2M20192020: -$155.5M-$155.5M2020+3%2021: -$79.6M-$79.6M2021−49%2022: $1.2M$1.2M20222023: -$8.5M-$8.5M20232024: -$6.1M-$6.1M2024−28%2025: -$4.4M-$4.4M2025−28%
Net income67985-$569.0K in 2025−100% since 2019
-$200.0M-$100.0M0$100.0M$200.0M2019: -$176.1M-$176.1M20192020: -$183.5M-$183.5M2020+4%2021: -$172.4M-$172.4M2021−6%2022: $112.0M$112.0M20222023: -$10.3M-$10.3M20232024: -$2.2M-$2.2M2024−79%2025: -$569.0K-$569.0K2025−74%

Every line of the income statement as filed: the last 2 fiscal years, latest first.5

Period ending2025-12-312024-12-31
License revenue$3.0M$1.8M
General and administrative$6.9M$6.1M
Write-off and impairment of patents$176.0K$1.3M
Depreciation & amortization$384.0K$509.0K
Total operating expenses$7.4M$7.9M
Loss from operations-$4.4M-$6.1M
Interest income, net$142.0K$135.0K
Sublease income$1.8M$1.4M
Miscellaneous income$1.7M$2.3M
Total other income$3.7M$3.8M
Loss from continuing operations before income taxes-$653.0K-$2.3M
Income tax benefit$31.0K
Net loss from continuing operations-$653.0K-$2.3M
Income from discontinued operations, net of income taxes$84.0K$131.0K
Net loss-$569.0K-$2.2M
Continuing operations (in Dollars per share)-$0-$0
Discontinued operations, net (in Dollars per share)$0$0
Net loss per common share, basic (in Dollars per share)-$0.05-$0.19
Continuing operations (in Dollars per share)-$0-$0
Discontinued operations, net (in Dollars per share)$0$0
Net loss per common share, diluted (in Dollars per share)-$0.05-$0.19
Weighted average common shares, basic (in Shares)11.6M shares11.5M shares
Weighted average common shares, diluted (in Shares)11.6M shares11.5M shares

Compare TherapeuticsMD, Inc. with another company

Leadership

Who has led TherapeuticsMD, Inc., and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Sky B. Kelley2009
  2. Robert Cambridge2009
  3. Robert G. Finizio2011–2021
  4. John C.k. Milligan Iv.2021
  5. Hugh O'Dowd2022
  6. Brian Bernick2022
  7. Mark A. Glickman2022
  8. Marlan D. Walker2023–now

Chair

  1. Robert G. Finizio2012
  2. Tommy Thompson2013

President

  1. Gerald L. Jensen2006–2007
  2. Gregory Woodhill2008
  3. Sky B. Kelley2009
  4. Robert Cambridge2009
  5. Jeffrey D. Howes2011
  6. John C.k. Milligan Iv.2011–2021
  7. Hugh O'Dowd2021

Chief financial officer

  1. Gregory Woodhill2008
  2. Donald R. Mastropietro2009
  3. Daniel A. Cartwright2011–2020
  4. James Darecca2020–2021
  5. Michael C. Donegan2022
2010201520202025
Board members and other officers (37)

Named in SEC Form D filings

People the company listed in its private-offering notices.

  • DirectorJustin C. Roberts named Oct 17, 2022 to Jul 11, 202361
  • DirectorAngus C. Russell named Aug 16, 2022 to Nov 14, 202262

Former names

  • AMHN, Inc.Sep 30, 2009 to Sep 14, 20113
  • CROFF ENTERPRISES INCNov 17, 1997 to Sep 4, 20093
  • CROFF OIL COOct 3, 1995 to Apr 1, 19973

Timeline

  1. Feb 13, 2023New chief executive Marlan D. Walker becomes CEO13
  2. Dec 9, 2022New chief executive Mark A. Glickman becomes CEO16
  3. Sep 16, 2022New chief executive Brian Bernick becomes CEO15
  4. Mar 28, 2022New chief executive Hugh O'Dowd becomes CEO14
  5. May 12, 2021New chief executive John C.k. Milligan Iv. becomes CEO17
  6. Oct 11, 2011New chief executive Robert G. Finizio becomes CEO18
  7. Aug 19, 2009New chief executive Robert Cambridge becomes CEO20
  8. Jul 31, 2009New chief executive Sky B. Kelley becomes CEO19

Filings

212 filings to the SEC since October 2021: 10 annual reports, 15 quarterly reports, 65 major events, 76 insider forms, 13 large holders, 4 private raises, 29 other. The latest 20:

  1. Aug 11, 202610-Q QUARTERLY REPORT EDGAR
  2. Aug 11, 20268-K CURRENT REPORT EDGAR
  3. Aug 5, 2026SCHEDULE 13G/A EDGAR
  4. May 12, 202610-Q QUARTERLY REPORT EDGAR
  5. May 12, 20268-K CURRENT REPORT EDGAR
  6. Apr 6, 2026SCHEDULE 13G EDGAR
  7. Apr 1, 202610-K/A ANNUAL REPORT EDGAR
  8. Apr 1, 2026NT 10-K NOTIFICATION OF LATE FILING EDGAR
  9. Mar 30, 20268-K CURRENT REPORT EDGAR
  10. Mar 30, 202610-K ANNUAL REPORT EDGAR
  11. Jan 21, 20268-K CURRENT REPORT EDGAR
  12. Dec 29, 20254 EDGAR
  13. Dec 16, 20258-K CURRENT REPORT EDGAR
  14. Nov 13, 20258-K CURRENT REPORT EDGAR
  15. Nov 12, 202510-Q QUARTERLY REPORT EDGAR
  16. Nov 5, 20254 EDGAR
  17. Nov 5, 20254 EDGAR
  18. Nov 5, 20254 EDGAR
  19. Nov 5, 20254 EDGAR
  20. Nov 3, 2025ARS EDGAR

The 212 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

32 open-market trades by officers, directors and large owners since October 2021: 16 buys and 16 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Dec 23, 2025Thompson Tommy GDirectorBuy8,400$1.67$14.0KForm 4
Apr 14, 2025Thompson Tommy GDirectorBuy325$1.00$325Form 4
Apr 14, 2025Walker Marlan DChief Executive OfficerBuy490$1.00$490Form 4
Apr 10, 2025Walker Marlan DChief Executive OfficerBuy1,167$0.86$1.0KForm 4
Apr 9, 2025Walker Marlan DChief Executive OfficerBuy1,136$0.87$988Form 4
Aug 22, 2024Collins Cooper C.DirectorBuy4,094$1.73$7.1KForm 4
Aug 21, 2024Collins Cooper C.DirectorBuy1,200$1.70$2.0KForm 4
Dec 7, 2023Walker Marlan DChief Executive OfficerSale4,550$2.24$10.2KForm 4
Dec 6, 2023Walker Marlan DChief Executive OfficerSale14,500$2.31$33.5KForm 4
Apr 26, 2023Walker Marlan DChief Executive OfficerSale692$3.64$2.5KForm 4
Apr 12, 2023Walker Marlan DChief Executive OfficerSale1,170$3.65$4.3KForm 4
Jan 27, 2023Donegan Michael CPrin. Fin. and Acctg. OfficerSale49$5.09$249Form 4
Jan 26, 2023Donegan Michael CPrin. Fin. and Acctg. OfficerSale1,648$5.08$8.4KForm 4
Jan 24, 2023Donegan Michael CPrin. Fin. and Acctg. OfficerSale7$5.31$37Form 4
Jan 23, 2023Donegan Michael CPrin. Fin. and Acctg. OfficerSale1,302$5.34$7.0KForm 4
Dec 30, 2022Rubric Capital Management LPDirectorSale29,000$1,333.00$38.7MForm 4
Dec 9, 2022Bernick BrianCo-Chief Executive OfficerSale320$6.31$2.0KForm 4
Dec 9, 2022Rubric Capital Management LPDirectorBuy14,825$6.09$90.3KForm 4
Dec 8, 2022Rosen David Efraim10% ownerBuy300$5.83$1.7KForm 4
Dec 7, 2022Naughton Gail KDirectorSale3,922$5.26$20.6KForm 4

All 32 trades can be filtered by person here when JavaScript is on.

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Money raised

Private offerings the company reported to the SEC on Form D.

  1. Jun 29, 2023Raised $1.1 million in a private offering of equity Form D: $5 million offered in all Form D
  2. Oct 28, 2022Raised $7 million in a private offering of equity Form D: 6 investors so far Form D
  3. Sep 30, 2022Raised $7 million in a private offering of equity Form D: 6 investors so far Form D
  4. Jul 29, 2022Raised $15 million in a private offering of equity Form D: 6 investors so far Form D

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 46. Change is in shares since the quarter before.

FundSharesValueShare of the fundChange
Rubric Capital Management LP1,192,191$2.6M0.0%No change
Clearline Capital LP635,222$1.4M0.1%No change
Vanguard Capital Management LLC353,697$781.7K0.0%No change
Tejara Capital Ltd344,482$761.3K0.3%−1,370
ADAR1 Capital Management, LLC342,447$756.8K0.0%+133,237
Renaissance Technologies LLC146,599$324.0K0.0%+399
Morgan Stanley129,217$285.6K0.0%No change
BlackRock, Inc.115,145$254.5K0.0%No change
Geode Capital Management, LLC105,849$234.0K0.0%−3,968
Citadel Advisors LLC86,095$190.3K0.0%+17,781
Vanguard Fiduciary Trust Co63,831$141.1K0.0%No change
State Street Corp30,100$66.5K0.0%No change
XTX Topco Ltd21,246$47.0K0.0%−6,241
Dimensional Fund Advisors LP19,719$43.6K0.0%+9,013
Northern Trust Corp18,556$41.0K0.0%+2,463
Bridgeway Capital Management, LLC17,000$37.6K0.0%No change
Osaic Holdings, Inc.15,198$33.6K0.0%+15,045
Vanguard Global Advisers, LLC4,937$10.9K0.0%No change
UBS Group AG4,660$10.3K0.0%+4,329
Tower Research Capital LLC (TRC)1,582$3.5K0.0%+73
SBI Securities Co., Ltd.1,263$2.8K0.0%+996
Smartleaf Asset Management LLC601$1.3K0.0%No change
Royal Bank Of Canada833$1.0K0.0%+643
Banque Cantonale Vaudoise7$1.0K0.0%No change
Jpmorgan Chase & Co293$6570.0%No change

13F reports cover disclosed long positions in U.S. stocks only.

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41
  42. 42
  43. 43
  44. 44
  45. 45
  46. 46
  47. 47
  48. 48
  49. 49
  50. 50
  51. 51
  52. 52
  53. 53
  54. 54
  55. 55
  56. 56
  57. 57
  58. 58
  59. 59
  60. 60
  61. 61
  62. 62
  63. 63
  64. 64
  65. 65
  66. 66
  67. 67
  68. 68